Overview

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to assess the safety and tolerability of Alpha-1 MP in adult Alpha1-antitrypsin deficient patients.
Phase:
Phase 3
Details
Lead Sponsor:
Grifols Therapeutics Inc.
Grifols Therapeutics LLC
Treatments:
Alpha 1-Antitrypsin
Protease Inhibitors
Protein C Inhibitor